Introduction {#s1}
============

Peptic ulcer is a chronic disease affecting up to 10% of the world's population, and the formation of peptic ulcers depends on the presence of increased acidic gastric juice and the decreased mucosal defenses ([@B29]). Non-steroidal anti-inflammatory drugs (NSAIDs) and *Helicobacter pylori* (*H. pylori*) infection are the two main factors disrupting the mucosal resistance to injury. Currently available conventional treatments of peptic ulcers include numerous pharmaceutical agents such as proton pump inhibitors, histamine H2-receptor antagonists, anticholinergics, antacids, antimicrobial agents, sucralfate, and bismuth, all of which are not fully effective, and are associated with numerous side effects including impotence, arrhythmia hematopoietic alterations hypersensitivity and gynecomastia ([@B14]; [@B47]). Consequently, there is still a strong need for new pharmacologically active entities for the therapeutic management of peptic ulcer. Histamine exerts its biological activities through interaction with four distinct histamine receptors (H1R--H4R) that belong to the G-protein coupled receptor (GPCR) family ([@B35]; [@B48]; [@B57]; [@B52]). H1R and H2R are found in the brain and periphery. Although H4Rs are present in the brain, they are predominately expressed in mast cells and leucocytes, whereas H3Rs are abundant in CNS ([@B3]; [@B4]; [@B2]; [@B5]; [@B1]; [@B6]; [@B48]). H3Rs are coupled to G~i~/G~o~-proteins and act as auto-receptors that control the synthesis and release of histamine in the CNS, while activation of H1R and H2R mediates slow excitatory postsynaptic potentials ([@B3]; [@B4]; [@B5]; [@B57]). Furthermore, H3Rs functioning as hetero-receptors can also regulate the release of other neurotransmitters like acetylcholine, glutamate, GABA, norepinephrine, serotonin, dopamine in variable brain regions ([@B13]). Mounting preclinical experimental evidences related numerous functional and behavioral effects to central H3R-mediation. The activation of such cerebral sites appears to stimulate a waking effect in cats ([@B59]; [@B33]; [@B34]), modulation of locomotor activity, anticonvulsant, antinociceptive, and procognitive actions in mice and rats ([@B17]; [@B72]; [@B18]; [@B36]; [@B56]; [@B50]; [@B55]; [@B54]; [@B57]; [@B51]; [@B52]; [@B53]). Interestingly, several polymorphisms have been detected for H3Rs ([@B28]; [@B11]), and H3Rs were found to be expressed in dimers ([@B61]; [@B8]) as well as co-expressed with other GPCRs, e.g. dopamine D1- or D2 receptors and adenosine A2A receptors in form of heteromers, and were linked with their modulating effects on several brain neurotransmitters, and therefore, their influence in mitigating numerous brain disorders ([@B24]; [@B25]; [@B39]; [@B49]; [@B37]). Notably, complexity of histamine H3R biology e.g. many isoforms, constitutive activity, the aforementioned heteromerization with other receptors (dopamine D2, D1, adenosine A2A), and pharmacology make it difficult to realize and evaluate the therapeutic potential of H3R antagonists ([@B30]).

Moreover, H3R has been identified in the gastrointestinal tract of the rat by immunohistochemistry, as immunoreactivity to H3R was exclusively localized to the endocrine cells scattered in the gastrointestinal mucosa, with positive cells being prominently abundant in the gastric fundus, while they were rarely found in the other regions ([@B27]).

Contrary, peripheral administration of the selective H3R agonist (*R*)-α-methylhistamine (RAMH) was found to inhibit pentagastrin-, 2-deoxy-D-glucose-, and peptone meal-stimulated gastric acid secretion in conscious cats as well as pentagastrin- and bombesin-induced hypersecretion in the conscious dog ([@B7]; [@B63]). The latter inhibitory effects were also found to be antagonized by co-administration of the H3R antagonist thioperamide ([@B63]). Moreover, numerous previous *in-vitro* experimental models of gastric injury showed that H3R agonist RAMH exerts protective effects with controversial interpretations ([@B43]; [@B44]; [@B42]; [@B41]). For instance, RAMH was likely to inhibit acid secretion via the suppression of histamine in isolated rat fundic enterochromafin-like cells, whereas an increased acid secretion secondary to reduced somatostatin secretion is reported in isolated mouse stomach ([@B43]; [@B44]; [@B42]; [@B41]). Furthermore, early *in-vivo* experiments showed that RAMH also potently inhibits gastric secretion by a number of indirect stimuli, e.g. vagal stimulation or pentagastrin ([@B7]; [@B71]). In addition, the role of H3Rs in the gastric mucosal gastrin expression and release by inhibiting secretion of somatostatin is still unclear, since the mechanism of action underlying this phenomenon remains unknown and is still a matter of study even though the presence of H3Rs on parasympathetic nerve terminals or on gastric paracrine cells has been proposed ([@B64]; [@B7]; [@B63]; [@B62]; [@B23]). In addition, unclear data were obtained with two highly selective H3R agonists, namely imetit ([@B26]) and immepip ([@B68]), which failed to share the gastroprotective effect of RAMH towards 0.6 N HCl-induced gastric damage in rat. However, it is well-known that many imidazole-containing ligands, including immepip and imetit, display affinity for the H4R ([@B32]), indicating that it might be postulated that histamine H4 receptor-mediated mechanisms may have influenced the interpretation of the observed results for immepip and imetit ([@B21]). The H4R was primarily identified on immunocompetent cells and cells of the hematopoietic lineage, such as mast cells, eosinophils, basophils, dendritic cells and T cells and a primary role in the inflammatory responses was postulated ([@B31]). Therefore, H4R antagonists are under development as novel antiallergic and anti-inflammatory drugs ([@B66]; [@B73]; [@B57]). Additionally, H4R expression was detected by immunohistochemistry in different areas of the gut ([@B16]; [@B58]; [@B12]; [@B10]; [@B40]) and protective effects have been evidenced, by the use of the H4R antagonist JNJ7777120 in various rodent models of gastric and intestinal damage ([@B65]; [@B67]; [@B19]), demonstrating the involvement of the H4Rs in gastrointestinal inflammation and ulcerogenesis ([@B20]).

To date, the potential contribution of a central H3R-mediated *in-vivo* regulatory influence in affecting gastric acid secretion has not been extensively explored and as a result cannot be ruled out completely. The latter considerations together with the aforementioned controversies in results obtained so far encouraged us to investigate the possible involvement of H3Rs in the control of gastric secretory function. Therefore, the objective of the current study was to determine whether interactions with H3Rs mediate *in vivo* gastroprotection applying the acidified ethanol-induced gastric ulcers and gastric acid secretion model in C57BL/6 mice, and following intragastric (i.g.) administration of the potent and selective H3R antagonist/inverse agonist M39 in presence and absence of the selective and potent H3R agonist RAMH ([**Figure 1**](#f1){ref-type="fig"}). Furthermore, the modulating effects of both H3R compounds on synthesis of somatostatin as well the production of prostaglandin E2 (PGE2) were investigated.

![Structure, *in-vivo* potency, and *in-vitro* antagonist affinities of H3R antagonist/inverse M39. ^a^Values previously published ([@B70]; [@B56]). Values for H1R and H2R were tested on guinea pig (gp).](fphar-10-00966-g001){#f1}

Material and Methods {#s2}
====================

Animals {#s2_1}
-------

C57BL/6 mice were purchased from Jackson Laboratory, Boulevard, Bethesda, MD 20892-4874, USA. They were bred at our animal facility. Adult male C57BL/6 mice (14--15 weeks) weighing 25--28 g were fasted for 24 h in wire mesh cages to avoid coprophagy but had free access to water ad libitum. The temperature of the animal room were maintained at 22 ± 2°C and with a 12--12 h dark--light cycle. This study was carried out in accordance with the recommendations of the European Communities Council Directive of 24 November 1986 (86/609/EEC), and was approved by the Institutional Animal Ethics Committee in the College of Medicine and Health Sciences/United Arab Emirates (Approval No. A38-13). All efforts were made to minimize animal suffering and to reduce the number of animals used.

Chemicals and Drugs {#s2_2}
-------------------

The H3R antagonist/inverse agonist 3-(1*H*-imidazol-4-yl)propyl but-3-en-1-ylcarbamate (M39) was synthesized by us in the Department of Technology and Biotechnology of Drugs (Kraków, Poland) as described previously ([@B70]) ([**Figure 1**](#f1){ref-type="fig"}). The compound M39 was synthesized by a modified Curtius reaction. In this reaction 4-pentenoic acid was reacted with diphenyl phosphorazidate (DPPA) under basic conditions leading to in situ obtained isocyanate intermediate, which then was reacted with 3-(1*H*-imidazol-yl)propanol hydrochloride to yield M39 ([@B70]).

All other drugs and chemicals were purchased from Sigma-Aldrich (St Louis, Missouri, USA). All drug solutions were freshly prepared. The enzyme immunoassay kit of Somatostatin was purchased from Phoenix Pharmaceuticals, Inc., Burlingame, CA 94010, USA. Enzyme immunoassay kit of PGE2 was purchased from R&D Systems, Minneapolis, MN, USA.

Gastric Acid Secretion *In Vivo* {#s2_3}
--------------------------------

Mice were initially anaesthetized with pentobarbitone (70 mg/kg) intraperitoneally (i.p.). Following general anesthesia, the pylorus was ligated according to the method of Shay et al, 1945 ([@B60]; [@B70]). Briefly, after the ligation, the animals were assigned into six different groups of six mice as follows: group 1: control, pretreated with distilled water (DW), group 2: RAMH (100 mg/kg, i.g.), group 3: H2R agonist DIM (10 mg/kg, i.g.), group 4: M39 (0.3 mg/kg, i.g.), group 5: M39 (0.3 mg/kg, i.g.)+RAMH (100 mg/kg, i.g.), and group 6: M39 (0.3 mg/kg, i.g.)+DIM (10 mg/kg, i.g.).

All the drug solutions were administered to the animals by gastric gavage. However, both groups 5 and 6 received H3R antagonist/inverse agonist M39 (0.3 mg/kg) followed by 15 min later administration of RAMH or DIM, respectively. The dose of 0.3 mg/kg of M39 was selected based on a dose response (0.3--3.0 mg/kg) pilot study as well as according to previous study conducted in Wistar rats ([@B45]). After 4 h, the animals were sacrificed by cervical dislocation and the gastric juice was collected for somatostatin assay and gastric contents were titrated against 0.01M sodium hydroxide for acid output which was calculated and expressed as mmol/4h.

Assay of Somatostatin in Gastric Juice {#s2_4}
--------------------------------------

Competitive Enzyme immunoassay of somatostatin in gastric juice was performed according to manufacturer's protocol. Briefly, the immunoplate was pre-coated with secondary antibody and the nonspecific binding sites were blocked. The secondary antibody was allowed to bind to the Fc fragment of the primary antibody whose Fab fragment was competitively bound by both biotinylated peptide and peptide standard or targeted peptide in samples during 2 incubation at room temperature (20--23°C) on orbital shaker at 300--400 rpm. The interaction of biotinylated peptide with streptavidin--horseradish peroxidase (SA--HRP) was catalyzed by the substrate solution. The intensity of the color is directly proportional to the amount of biotinylated peptide-- SA--HRP complex but inversely proportional to the amount of the peptide in standard solutions or samples. The color intensity was read at 450 nm with a microplate reader (Tecan Group Ltd., Männedorf, Switzerland). Somatostatin concentration was expressed as nanogram per ml of gastric juice.

Gastric Acid Ulcer *In Vivo* {#s2_5}
----------------------------

Acidified ethanol (AE; 60% ethanol in 150 mM hydrochloric acid) was used to induce gastric ulcers in the mice. The mice were divided into four different groups of 6 animals each. Each group received either DW (control), or RAMH (100 mg kg), or M39 (0.3 mg/kg) 15 min prior to RAMH (100 mg/kg) administration as a gastric gavage. After 30 min of DW or drug administration, AE was given orally to each animal at a dose of 0.2 ml per mouse and the animals were killed 1 h later by cervical dislocation. The abdomen was incised and the stomach removed. The stomach was cut open along the greater curvature and rinsed with saline to remove any adherent food particles and mucus. The opened stomach was then spread on a sheet of cork so as to have a clear macroscopic view of the gastric mucosa. The total lengths of the haemorrhagic lesions, which were approximately 1 mm in width and formed in the glandular portion of the gastric mucosa, were taken as ulcer index (UI). An observer unaware of the drug treatments confirmed the ulcer index. The use of 60% ethanol in 150 mM HCl as an ulcerogenic agent was based on our earlier observation and of others that ethanol 50% and over provided a reproducible model of gastric damage ([@B46]; [@B38]; [@B15]; [@B9]).

### Preparation of Gastric Mucosal Homogenate {#s2_5_1}

Briefly, after dissection, stomachs were washed with ice-cold PBS, and the gastric mucosa was rapidly scraped from the underlying tissue layers of stomach on ice. The mucosa was weighed, minced by forceps, and homogenized with 3 volumes of cold phosphate buffer (PBS 0.1 mol/L, pH 7.4, containing 1 mM EDTA and 10 μM indomethacin) per gram of tissue using a polytron homogenizer (IKA laboratory, Germany).

Assay of PGE2 in Gastric Mucosa {#s2_6}
-------------------------------

Competitive Enzyme immunoassay of PGE2 in gastric mucosal was performed according to manufacturer's protocol. This assay was based on the forward sequential competitive binding technique in which PGE2 present in a sample competed with horseradish peroxidase (HRP)-labeled PGE2 for a limited number of binding sites on a mouse monoclonal antibody. PGE2 in the sample was allowed to bind to the antibody in the first incubation of one hour at room temperature on a horizontal orbital microplate shaker (0.12" orbit) at 500 ± 50 rpm. During the second incubation, HRP-labeled PGE~2~ was bound to the remaining antibody sites. Unbound materials were washed and substrate solution was added to the wells to determine the bound enzyme activity. The color development was stopped, and the absorbance was read at 450 nm. The intensity of the color was inversely proportional to the concentration of PGE2 in the sample. PGE2 concentration was expressed as picogram per milligram of mucosal tissue.

Statistical Analysis {#s2_7}
--------------------

Data was analyzed statistically using SPSS 25.0 software (IBM Middle East, Dubai, UAE). The means of the data are presented with the standard error mean (SEM). The results were analyzed using independent *t*-test to determine the significance of the mean between the groups. Values of *P* \< 0.05 were considered significant.

Results {#s3}
=======

Acidified Ethanol-Induced Gastric Mucosal Lesions {#s3_1}
-------------------------------------------------

### Macroscopy {#s3_1_1}

Acidified ethanol determined the formation of red to black linear streaks in the glandular portion of the stomach of vehicle-treated group (ulcer index of 35.5 ± 4, n=6) ([**Figures 2**](#f2){ref-type="fig"} and [**3**](#f3){ref-type="fig"}). Mucosal damage caused by acidified ethanol was substantially reduced by RAMH at the dose of 100 mg/kg (ulcer index of 6.0 ± 1.46, n = 6; *P* \< 0.001). Similarly, M39 when administered alone at a dose of 0.3 mg/kg significantly reduced the mucosal damage (ulcer index of 9.0 ± 1.41, n = 6; *P* \< 0.001) ([**Figures 2**](#f2){ref-type="fig"} and [**3**](#f3){ref-type="fig"}). However, RAMH and M39 (0.3 mg/kg) failed to completely abrogate each other's protections when compared to vehicle-, RAMH(100mg/kg)-, M39(0.3mg)-group with ulcer index of 15.67 ± 1.44, n = 6; both *P* \< 0.05 for RAMH(100mg)+M39(0.3mg)-treated group versus RAMH- or M39(0.3mg)-treated group) ([**Figures 2**](#f2){ref-type="fig"} and [**3**](#f3){ref-type="fig"}).

![Photomicrographs of stomachs showing the effect of vehicle, H3R agonist (*R*)-α-methylhistamine, and test compound M39 on stomach ulcer of C57BL/6 mice. Micrographs are the results of five to six such experiments. showing the effect on acidified ethanol in **(A)** vehicle-, **(B)** RAMH(100mg/kg)-, **(C)** M39(0.3mg)-, and **(D)** M39(0.3mg)+RAMH(100mg)-treated group in reducing the stomach ulcers.](fphar-10-00966-g002){#f2}

![Effects of vehicle, H3R agonist (*R*)-α-methylhistamine, and test compound M39 on acidified ethanol-induced ulcer index in C57BL/6 mice. \*\**P* \< 0.01 vs. vehicle-treated group. \*\*\**P* \< 0.001 vs. vehicle-treated group. ^\#^ *P* \< 0.05 vs. RAMH- or M39(0.3mg)-treated group. Data represent mean ± SEM (n = 5--6).](fphar-10-00966-g003){#f3}

### PGE2 Synthesis {#s3_1_2}

The observed results show that both the H3R agonist RAMH (100 mg/kg) and M39 (0.3 mg/kg) administered separately significantly increased the synthesis of mucosal PGE2 with values of 38971.17 ± 624.44 and 37828.98 ± 782.45 pg/mg of gastric mucosa, respectively (*P* \> 0.001 for RAMH- and M39-treated group versus vehicle-treated group), respectively. However, co-administration of both M39 and RAMH abrogated each other's stimulating effect on PGE2 synthesis with a value of 26650.72 ± 3068.16 pg/mg (p = 0.65 for M39+RAMH-treated group versus vehicle-treated group) ([**Figure 4**](#f4){ref-type="fig"}).

![Effect of vehicle, H3R agonist (*R*)-α-methylhistamine, and test compound M39 on PGE2 synthesis in the stomach mucosa of C57BL/6 mice. \*\*\**P* \< 0.001 vs. vehicle-treated group. ^\#^ *P* \< 0.05 vs. RAMH- or M39(0.3mg)-treated group. Results are expressed as the mean ± standard error of six replicates.](fphar-10-00966-g004){#f4}

Somatostatin Synthesis {#s3_2}
----------------------

The results observed show that only DIM significantly decreased the synthesis of somatostatin (12.83 ± 0.36 ng/mL for vehicle-treated group versus 9.21 ± 1.25 ng/mL for DIM-treated group; *P* \< 0.05). However, RAMH and M39 (0.3 and 3 mg) failed to modulate the biosynthesis of somatostatin with values of 12.47 ± 1.33, 13.18 ± 0.80, and 11.21 ± 1.10, respectively (all *P* values \> 0.05) ([**Figure 5**](#f5){ref-type="fig"}).

![Effects of vehicle, H2R agonist dimaprit, H3R agonist (*R*)-α-methylhistamine, and test compound M39 on gastric somatostatin concentration in C57BL/6 mice. Data represent mean ±SEM (n = 5--6). \**P* \< 0.05 vs. vehicle-treated group.](fphar-10-00966-g005){#f5}

Gastric Acid Secretion {#s3_3}
----------------------

In the juice present in the stomach, the H2R agonist DIM and the H3R agonist RAMH caused a significant increase in the volume of gastric juice with a concomitant marked and significant increase in the amount of titratable acidity ([**Figure 6**](#f6){ref-type="fig"}). The stimulation of acid secretion by RAMH, was completely reversed by prior treatment with the H3R antagonist/inverse agonist M39 (p = 0.96 for vehicle-treated group versus RAMH+M39(0.3mg)-treated group) ([**Figure 6**](#f6){ref-type="fig"}). However, M39 (0.3 mg/kg) failed to reverse the effect observed by DIM (p = 0.63 for DIM-treated group versus DIM+M39(0.3mg)-treated group) ([**Figure 6**](#f6){ref-type="fig"}). In addition, H3R antagonist/inverse agonist M39 (0.3 and 3 mg/kg) had no effect on titratable acidity when administered alone as compared to vehicle-treated group (p= 0.36 and p= 0.36, for M39(0.3mg)-treated group versus vehicle-treated group and M39(3mg)-treated group versus vehicle-treated group, respectively) ([**Figure 6**](#f6){ref-type="fig"}).

![Effects of vehicle, H2R agonist dimaprit, H3R agonist (*R*)-α-methylhistamine, and test compound M39 on gastric acid secretion in the stomachs of C57BL/6 mice. Data represent mean ±SEM (n = 5--6). \**P* \< 0.05 vs. vehicle-treated group. \*\*\**P* \< 0.001 vs. vehicle-treated group. ^\#^ *P* \< 0.05 vs. RAMH-treated group.](fphar-10-00966-g006){#f6}

Discussion {#s4}
==========

The current study indicates that RAMH efficiently preserves the integrity of mice gastric mucosa against damage with acidified ethanol, as measured using macroscopic evaluation ([**Figure 2**](#f2){ref-type="fig"}). In the current *in-vivo* gastric ulcer model, the H3R agonist RAMH and the H3R antagonist/inverse agonist M39 exhibited comparable gastroprotective effects as obviously observed by ulcer indices ([**Figure 3**](#f3){ref-type="fig"}). Moreover, the results observed show that the gastroprotective effect provided by H3R agonist RAMH was partly reversed when mice were pretreated with M39 as measured on the level of ulcer index, indicating that, in addition to histaminergic pathways through activation of H3Rs, the protective effects might be attributed to mechanisms other than histaminergic neurotransmission. These results are in agreement with a previous study which showed that H3R is involved in the protection of rat stomach against concentrated hydrochloric acid. However, the functional role of the H4R is still to be defined, although selective agonists induce proulcerogenic effects under hydrochloric acid challenge ([@B21]). Furthermore, both compounds when administered separately significantly increased the level of synthesized PGE2, an effect that might explain the gastroprotection provided by both compounds ([**Figure 4**](#f4){ref-type="fig"}). Interestingly, the stimulating effect observed for RAMH on PGE2 synthesis was completely abolished when mice were pretreated with the potent H3R antagonist M39 ([**Figure 4**](#f4){ref-type="fig"}). However, the H3R agonist RAMH as well as the H3R antagonist/inverse agonist M39 failed in the current study to modify the synthesis of somatostatin ([**Figure 5**](#f5){ref-type="fig"}). The latter results are in disagreement with previous studies in which modulation of H3Rs resulted in a significant alteration of somatostatin synthesis, demonstrating that the mechanisms responsible for the protective action observed for RAMH and H3R antagonist/inverse agonist M39 appear to be unrelated to their effects on somatostatin synthesis ([@B43]; [@B44]; [@B42]; [@B45]). Moreover, protection by RAMH is not attributable to a modulation in gastric acidity, since RAMH increased acid production and secretion, although significantly lower than the effect observed for the H2R agonist DIM ([**Figure 6**](#f6){ref-type="fig"}). Furthermore, the H3R antagonist/inverse agonist M39 failed to modify gastric acid secretion which is in agreement with previous studies in which ciproxifan was found to be not effective in increasing or decreasing gastric acid secretion ([@B45]). Interestingly, the effect of RAMH, but not of DIM, on increasing gastric acid secretion was completely abrogated when mice were pretreated with M39 ([**Figure 6**](#f6){ref-type="fig"}). These observations clearly indicate that there is no association between the effects observed for RAMH and M39 on gastric acid secretion and their influence on the susceptibility of the mucosa to lesion formation. Notably, there is still some debate as to whether the stimulation of gastric acid secretion evoked by RAMH in rodents is attributable to H3R activation ([@B69]; [@B22]). However, the present failure of H3R antagonist/inverse agonist M39 to influence RAMH-stimulated acid secretion at doses causing a complete inhibition of RAMH-induced increase of PGE2 synthesis appears to rule out the involvement of H3Rs in the acid secretory response to RAMH. Therefore, caution is required when interpreting the effects observed for H3R agonists or antagonists/inverse agonists in preclinical ulcer models. Accordingly, the differences in animal species together with the type of experimental conduct and the routes by which the test compounds are administered should be considered for comparison when interpreting results observed. Additionally, it should be taken into consideration that RAMH and M39 are likely to differ significantly in their pharmacokinetic properties when it comes to testing them in *in-vivo* models.

Conclusion {#s5}
==========

The partial M39-provided inhibition of the gastroprotection exerted by RAMH validate the hypothesis that RAMH is capable of counteracting mucosal damage mediated through histamine H3Rs. However, here we present the first evidence that agonistic interaction with H3Rs are actively involved in the maintenance of gastric mucosal integrity by modulating PGE2 as well as gastric acid secretion, with no apparent role in the regulation of inhibitory influence of somatostatin. However, the observed results showed that M39 reverses the effects of RAMH on gastroprotection and PGE2 production, demonstrating that it is still difficult to provide a conclusion since both compounds were able to show effects on their own, and combination of both counteracts the effects of either alone. Therefore, the exact mechanistic background for the mediated protective effects of RAMH as well as M39 still continues to be a challenge.
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